4SC Investor
4SC discovers and develops targeted, small-molecule drugs for the treatment of cancer and autoimmune diseases.
Headquarters:
Germany
Last Funding Type:
Post-IPO Equity
Investors Number:
9
Last Funding Date:
2019-11-12
Employee Number:
51-100
Total Funding:
94700000 EUR
Founded Date:
1997
Estimated Revenue:
$1M to $10M
Industry:
Energetic Process
Funding Status:
IPO